Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients

Verónica González-Calle, Abigail Slack, Niamh Keane, Susan Luft, Kathryn E. Pearce, Rhett P. Ketterling, Tania Jain, Sintosebastian Chirackal, Craig Reeder, Joseph R Mikhael, Pierre Noel, Angela Mayo, Roberta H. Adams, Gregory Ahmann, Esteban D Braggio, Alexander Keith Stewart, Peter Leif Bergsagel, Scott A. van Wier, Rafael Fonseca

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The International Myeloma Working Group has proposed the Revised International Staging System (R-ISS) for risk stratification of multiple myeloma (MM) patients. There are a limited number of studies that have validated this risk model in the autologous stem cell transplant (ASCT) setting. In this retrospective study, we evaluated the applicability and value for predicting survival of the R-ISS model in 134 MM patients treated with new agents and ASCT at the Mayo Clinic in Arizona and the University Hospital of Salamanca in Spain. The patients were reclassified at diagnosis according to the R-ISS: 44 patients (33%) had stage I, 75 (56%) had stage II, and 15 (11%) had stage III. After a median follow-up of 60 months, R-ISS assessed at diagnosis was an independent predictor for overall survival (OS) after ASCT, with median OS not reached, 111 and 37 months for R-ISS I, II and III, respectively (P < 0.001). We also found that patients belonging to R-ISS II and having high-risk chromosomal abnormalities (CA) had a significant shorter median OS than those with R-ISS II without CA: 70 vs. 111 months, respectively. Therefore, this study lends further support for the R-ISS as a reliable prognostic tool for estimating survival in transplant myeloma patients and suggests the importance of high-risk CA in the R-ISS II group.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalAnnals of Hematology
DOIs
StateAccepted/In press - Apr 6 2018

Fingerprint

Multiple Myeloma
Transplants
Survival
Chromosome Aberrations
Stem Cells
Spain
Retrospective Studies

Keywords

  • Autologous transplantation
  • Myeloma
  • Prognostic factor
  • R-ISS

ASJC Scopus subject areas

  • Hematology

Cite this

Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. / González-Calle, Verónica; Slack, Abigail; Keane, Niamh; Luft, Susan; Pearce, Kathryn E.; Ketterling, Rhett P.; Jain, Tania; Chirackal, Sintosebastian; Reeder, Craig; Mikhael, Joseph R; Noel, Pierre; Mayo, Angela; Adams, Roberta H.; Ahmann, Gregory; Braggio, Esteban D; Stewart, Alexander Keith; Bergsagel, Peter Leif; van Wier, Scott A.; Fonseca, Rafael.

In: Annals of Hematology, 06.04.2018, p. 1-10.

Research output: Contribution to journalArticle

González-Calle, V, Slack, A, Keane, N, Luft, S, Pearce, KE, Ketterling, RP, Jain, T, Chirackal, S, Reeder, C, Mikhael, JR, Noel, P, Mayo, A, Adams, RH, Ahmann, G, Braggio, ED, Stewart, AK, Bergsagel, PL, van Wier, SA & Fonseca, R 2018, 'Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients', Annals of Hematology, pp. 1-10. https://doi.org/10.1007/s00277-018-3316-7
González-Calle, Verónica ; Slack, Abigail ; Keane, Niamh ; Luft, Susan ; Pearce, Kathryn E. ; Ketterling, Rhett P. ; Jain, Tania ; Chirackal, Sintosebastian ; Reeder, Craig ; Mikhael, Joseph R ; Noel, Pierre ; Mayo, Angela ; Adams, Roberta H. ; Ahmann, Gregory ; Braggio, Esteban D ; Stewart, Alexander Keith ; Bergsagel, Peter Leif ; van Wier, Scott A. ; Fonseca, Rafael. / Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. In: Annals of Hematology. 2018 ; pp. 1-10.
@article{32f851420ab54950b140d8a43702e5bf,
title = "Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients",
abstract = "The International Myeloma Working Group has proposed the Revised International Staging System (R-ISS) for risk stratification of multiple myeloma (MM) patients. There are a limited number of studies that have validated this risk model in the autologous stem cell transplant (ASCT) setting. In this retrospective study, we evaluated the applicability and value for predicting survival of the R-ISS model in 134 MM patients treated with new agents and ASCT at the Mayo Clinic in Arizona and the University Hospital of Salamanca in Spain. The patients were reclassified at diagnosis according to the R-ISS: 44 patients (33{\%}) had stage I, 75 (56{\%}) had stage II, and 15 (11{\%}) had stage III. After a median follow-up of 60 months, R-ISS assessed at diagnosis was an independent predictor for overall survival (OS) after ASCT, with median OS not reached, 111 and 37 months for R-ISS I, II and III, respectively (P < 0.001). We also found that patients belonging to R-ISS II and having high-risk chromosomal abnormalities (CA) had a significant shorter median OS than those with R-ISS II without CA: 70 vs. 111 months, respectively. Therefore, this study lends further support for the R-ISS as a reliable prognostic tool for estimating survival in transplant myeloma patients and suggests the importance of high-risk CA in the R-ISS II group.",
keywords = "Autologous transplantation, Myeloma, Prognostic factor, R-ISS",
author = "Ver{\'o}nica Gonz{\'a}lez-Calle and Abigail Slack and Niamh Keane and Susan Luft and Pearce, {Kathryn E.} and Ketterling, {Rhett P.} and Tania Jain and Sintosebastian Chirackal and Craig Reeder and Mikhael, {Joseph R} and Pierre Noel and Angela Mayo and Adams, {Roberta H.} and Gregory Ahmann and Braggio, {Esteban D} and Stewart, {Alexander Keith} and Bergsagel, {Peter Leif} and {van Wier}, {Scott A.} and Rafael Fonseca",
year = "2018",
month = "4",
day = "6",
doi = "10.1007/s00277-018-3316-7",
language = "English (US)",
pages = "1--10",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients

AU - González-Calle, Verónica

AU - Slack, Abigail

AU - Keane, Niamh

AU - Luft, Susan

AU - Pearce, Kathryn E.

AU - Ketterling, Rhett P.

AU - Jain, Tania

AU - Chirackal, Sintosebastian

AU - Reeder, Craig

AU - Mikhael, Joseph R

AU - Noel, Pierre

AU - Mayo, Angela

AU - Adams, Roberta H.

AU - Ahmann, Gregory

AU - Braggio, Esteban D

AU - Stewart, Alexander Keith

AU - Bergsagel, Peter Leif

AU - van Wier, Scott A.

AU - Fonseca, Rafael

PY - 2018/4/6

Y1 - 2018/4/6

N2 - The International Myeloma Working Group has proposed the Revised International Staging System (R-ISS) for risk stratification of multiple myeloma (MM) patients. There are a limited number of studies that have validated this risk model in the autologous stem cell transplant (ASCT) setting. In this retrospective study, we evaluated the applicability and value for predicting survival of the R-ISS model in 134 MM patients treated with new agents and ASCT at the Mayo Clinic in Arizona and the University Hospital of Salamanca in Spain. The patients were reclassified at diagnosis according to the R-ISS: 44 patients (33%) had stage I, 75 (56%) had stage II, and 15 (11%) had stage III. After a median follow-up of 60 months, R-ISS assessed at diagnosis was an independent predictor for overall survival (OS) after ASCT, with median OS not reached, 111 and 37 months for R-ISS I, II and III, respectively (P < 0.001). We also found that patients belonging to R-ISS II and having high-risk chromosomal abnormalities (CA) had a significant shorter median OS than those with R-ISS II without CA: 70 vs. 111 months, respectively. Therefore, this study lends further support for the R-ISS as a reliable prognostic tool for estimating survival in transplant myeloma patients and suggests the importance of high-risk CA in the R-ISS II group.

AB - The International Myeloma Working Group has proposed the Revised International Staging System (R-ISS) for risk stratification of multiple myeloma (MM) patients. There are a limited number of studies that have validated this risk model in the autologous stem cell transplant (ASCT) setting. In this retrospective study, we evaluated the applicability and value for predicting survival of the R-ISS model in 134 MM patients treated with new agents and ASCT at the Mayo Clinic in Arizona and the University Hospital of Salamanca in Spain. The patients were reclassified at diagnosis according to the R-ISS: 44 patients (33%) had stage I, 75 (56%) had stage II, and 15 (11%) had stage III. After a median follow-up of 60 months, R-ISS assessed at diagnosis was an independent predictor for overall survival (OS) after ASCT, with median OS not reached, 111 and 37 months for R-ISS I, II and III, respectively (P < 0.001). We also found that patients belonging to R-ISS II and having high-risk chromosomal abnormalities (CA) had a significant shorter median OS than those with R-ISS II without CA: 70 vs. 111 months, respectively. Therefore, this study lends further support for the R-ISS as a reliable prognostic tool for estimating survival in transplant myeloma patients and suggests the importance of high-risk CA in the R-ISS II group.

KW - Autologous transplantation

KW - Myeloma

KW - Prognostic factor

KW - R-ISS

UR - http://www.scopus.com/inward/record.url?scp=85045062446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045062446&partnerID=8YFLogxK

U2 - 10.1007/s00277-018-3316-7

DO - 10.1007/s00277-018-3316-7

M3 - Article

SP - 1

EP - 10

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

ER -